All In Biotech

Drug Trial Radar · NCT06319846

Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4)

A Multicenter, Double-blind, Double-dummy, Randomized Clinical Trial Comparing the Efficacy and Safety of Tirofiban Versus Placebo in Preventing Recurrence of Stroke for Patients With Intracranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4)

Last checked: Nov 20, 2026Latest source record: Jul 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 4,674 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

4,674

Planned (sponsor's estimate)

Start

Jul 11, 2024

Primary completion

Oct 2025

Study completion Dec 2026

Sponsor

Lead sponsor
Beijing Tiantan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, double-blind, double-dummy, randomized clinical trial comparing the efficacy and safety of tirofiban versus placebo in preventing recurrence of stroke for patients with intracranial artery stenosis and high-risk acute non-disabling cerebrovascular events.

Conditions

  • Ischemic Stroke, Acute
  • TIA
  • Symptomatic Intracranial Artery Stenosis

Interventions

  • TirofibanDrug

    Initial infusion of tirofiban 0.4μg/kg body weight/minute for 30 minutes (a maximum dose of 1mg) within 24 hours of symptom onset, followed by a continuous infusion of tirofiban 0.1μg/kg body weight/minute for 48 hours.

  • PlaceboDrug

    Initial infusion of saline placebo for 30 minutes within 24 hours of symptom onset, followed by a continuous infusion of placebo for 48 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Any new ischemic stroke at 3-monthTime frame: at 3-month
  2. Type 3 or 5 bleeding events according to the BARC criteria at 3-monthTime frame: at 3-month

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • The 2nd Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Recruiting

  • People's Hospital of Qihe County

    Dezhou, Shandong, China · Recruiting

  • Liaocheng People's Hospital(Liaocheng Brain Hospital)

    Liaocheng, Shandong, China · Recruiting

  • Third People's Hospital of Liaocheng

    Liaocheng, Shandong, China · Recruiting

  • Yantai Penglai traditional Chinese medicine hospital

    Yantai, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.